



Phone : 844-800-5377

Fax : 214-782-9155

HEMOPHILIA & BLEEDING DISORDERS ENROLLMENT FORM

Referral Date: _____ Ship to: Home Office Other _____

PATIENT INFORMATION

Patient Name: _____ Date of Birth: _____ Gender: _____
 Home Phone: _____ Cell Phone: _____ Email: _____
 Address: _____ City: _____ State: _____ Zip: _____
 Emergency Contact: _____ Emergency Phone: _____

INSURANCE INFORMATION

Please fax copy of prescription and insurance cards with this form if available (front and back)

Primary Insurance: _____
 ID #: _____ Group #: _____
 Secondary Insurance: _____
 ID #: _____ Group #: _____
 Prescription Card ID: _____ BIN #: _____
 PCN #: _____ Group #: _____

PRESCRIBER INFORMATION

Prescriber Name: _____
 DEA #: _____ NPI #: _____
 Address: _____
 City: _____ State: _____ Zip: _____
 Phone: _____ Fax: _____
 Contact Person: _____

DIAGNOSIS

D66 - Hemophilia A (Factor VIII Deficiency)
 D67 - Hemophilia B (Factor IX Deficiency)
 D68.1 - Hemophilia C (Factor XI Deficiency)
 D68.2 - Hereditary Deficiency of other Clotting Factors
 D68.0 - Von Willebrand's Disease
 D69.9 - Hemorrhagic Condition, Unspecified
 D68.4 - Acquired Coagulation Factor Deficiency
 D68.8 - Other Specified Coagulation Defects
 Other: _____

PATIENT EVALUATION

Patient Weight: _____ kg lbs
 Patient Height: _____ cm in
 Allergies: _____
 Inhibitor: No Historical Current
 Current Medications: _____
 Factor Deficiency: Severe (<1%) Moderate (1-5%) Mild (>5%)
 Line Access: Port PICC PIV Butterfly Other: _____
 Injection Training/Home Health RN visit is necessary: Yes No
 Site of Care: Home MD Office Other: _____

PRESCRIPTION INFORMATION RX to include diluents, needles, syringes, ancillary supplies, home medical equipment to administer infusion.

Factor VIII	<input type="checkbox"/> Advate® <input type="checkbox"/> Adynovate® <input type="checkbox"/> Afstyla® <input type="checkbox"/> Alphanate® <input type="checkbox"/> Altuviio® <input type="checkbox"/> Corifact® <input type="checkbox"/> Eloctate® <input type="checkbox"/> Esperoct® <input type="checkbox"/> Hemofil® M <input type="checkbox"/> Humate-P® <input type="checkbox"/> Jivi® <input type="checkbox"/> Koate-DVI® <input type="checkbox"/> Kovaltry® <input type="checkbox"/> NovoEight® <input type="checkbox"/> Nuwiq® <input type="checkbox"/> Recombinate® <input type="checkbox"/> Tretten® <input type="checkbox"/> Vonvendi® <input type="checkbox"/> Wilate® <input type="checkbox"/> Xyntha® <input type="checkbox"/> Xyntha Solofuse®
Factor IX	<input type="checkbox"/> AlphaNine® <input type="checkbox"/> Alprolix® <input type="checkbox"/> Benefix® <input type="checkbox"/> Idelvion® <input type="checkbox"/> Ixinity® <input type="checkbox"/> Profilnine® <input type="checkbox"/> Rebinyn® <input type="checkbox"/> Rixubis®
Factor X	<input type="checkbox"/> Coagadex®
Inhibitor Therapies	<input type="checkbox"/> Feiba® NF <input type="checkbox"/> NovoSeven® <input type="checkbox"/> Sevenfact®

Dose and Directions	Quantity	Refills
	<input type="checkbox"/> Prophylaxis: Infuse _____ units (+/- _____ %) slow IV-push every _____ <input type="checkbox"/> Breakthrough Bleed: For bleeding episodes: Infuse _____ units (+/- _____ %) slow IV-push _____ for a total of _____ doses. For minor bleeds: Infuse _____ IU every _____ For major bleeds: Infuse _____ IU every _____ <input type="checkbox"/> Other: _____	# of Prophy Doses
	# of PRN Doses	

Subcutaneous	<input type="checkbox"/> Alhemo®	Dose and Directions <input type="checkbox"/> 60mg/1.5mL PEN <input type="checkbox"/> 150mg/1mL PEN <input type="checkbox"/> Loading Dose: Inject _____ subcutaneously once on Day 1, followed by _____ mg subcutaneously once daily until individualization of maintenance dose. <input type="checkbox"/> Maintenance Dose: Inject _____ mg subcutaneously once daily.		
---------------------	----------------------------------	--	--	--



Phone : 844-800-5377

Fax : 214-782-9155

HEMOPHILIA & BLEEDING DISORDERS ENROLLMENT FORM

PRESCRIPTION INFORMATION RX to include diluents, needles, syringes, ancillary supplies, home medical equipment to administer infusion.

	Dose and Directions	Quantity	Refills
Subcutaneous	<input type="checkbox"/> Hemlibra® <input type="checkbox"/> 12mg/0.4mL <input type="checkbox"/> 30mg/mL <input type="checkbox"/> 60mg/0.4mL <input type="checkbox"/> 105mg/0.7mL <input type="checkbox"/> 150mg/1mL <input type="checkbox"/> 300mg/2mL <input type="checkbox"/> Initial dose: 3mg/kg subcutaneously once weekly for 4 weeks <input type="checkbox"/> Maintenance dose: <input type="checkbox"/> 1.5mg/kg subcutaneously every week <input type="checkbox"/> 3mg/kg subcutaneously every 2 weeks <input type="checkbox"/> 6mg/kg subcutaneously every 4 weeks		
	<input type="checkbox"/> Hympavzi® <input type="checkbox"/> 150mg/mL PFS <input type="checkbox"/> 150mg/mL PEN <input type="checkbox"/> Loading Dose: Inject 300mg (two 150mg injections) subcutaneously once <input type="checkbox"/> Maintenance Dose: Inject 150mg subcutaneously every week		
Other			
Flush Protocol	<input type="checkbox"/> NaCl 0.9% 5mL <input type="checkbox"/> NaCl 0.9% 10mL	Use as needed before/after infusion to maintain IV access and patency, or as final flush.	
	<input type="checkbox"/> Heparin 10 units per mL <input type="checkbox"/> Heparin 100 units per mL		
Other Medication	<input type="checkbox"/> Amicar® Tablet/Syrup Directions: _____		
	<input type="checkbox"/> Lidocaine 2.5%/Prilocaine 2.5% Cream (May dispense Lidocaine 4%) Directions: Apply to injection site(s) at least 1 hour prior to needle insertion.		
Additional Orders			

PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

By signing this form and using this pharmacy's services, you are authorizing this pharmacy to serve as your prior authorization designated agent in dealing with prescription and medical insurance companies.

<input type="checkbox"/> May Substitute/Product Selection Permitted/Substitution Permissible Prescriber Signature _____ Date _____	<input type="checkbox"/> Dispense as Written/Brand Medically Necessary/Do Not Substitute/No Substitution/May Not Substitute Prescriber Signature _____ Date _____
--	---

CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "No Substitution" _____ NY & Iowa providers, please submit electronic prescription.

IMPORTANT NOTICE: This message may contain privileged and confidential information and is intended only for the individual named. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document by mistake, then destroy this document. Please direct all verification or notification to EPSRx or any of its subsidiaries using the contact information provided on this coversheet. This referral form is intended to assist with the processing of the patient's prescription and can be used at any pharmacy of the patient's choosing. It is not limited to the pharmacy listed on the form, nor does it imply that the patient is required to fill their prescription at a specific location. Patients maintain the right to select the pharmacy that best meets their needs. Please refer to TSBP Rule 281.7(15) for further guidance.